Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Fortis Healthcare...

    Fortis Healthcare rejects over pricing of drugs charge

    Written by Ruby Khatun Khatun Published On 2017-12-18T11:00:17+05:30  |  Updated On 16 Aug 2021 2:17 PM IST

    New Delhi: Fortis Healthcare has rejected charges of overpricing the medicines that it is giving to its patients.


    In a statement, it said, "Fortis Healthcare does not charge any drug or consumables above the printed MRP and there is No Violation of Drug Price Control Order. It should also be noted that our end price to the patient is very much in line with what other private hospitals in India charge."


    "Looking at individual prices of any single item as a stand-alone takes the margin/profit topic out of context. To understand the total profit scenario and overall business performance, one should look at the financial margins for the Fortis hospital business. As such, it should be noted that the Fortis hospital business reported operating profit (EBITDA) over the last four published quarters of 5 to 6 percent and a negative PAT(profit after tax) for the same period of time."


    The statement comes days after a Haryana Government appointed panel said that Fortis Healthcare, Gurgaon, had committed some irregularities with regard to drug pricing. The regulator has asked Fortis for copies of bills for allegedly overcharging a patient at their Gurugram facility.


    The hospital charged Jayant Singh nearly Rs 16 lakh for the treatment of his seven-year-old daughter, who died of dengue.


    The National Pharmaceutical Pricing Authority has also served a show cause notice to healthcare chain Fortis, asking it for copies of bills in a case where its hospital in Gurugram allegedly overcharged a patient suffering from dengue.


    The hospital had asked Jayant Singh, a resident of Dwarka in Delhi, to pay nearly Rs 16 lakh for treating his seven-year-old daughter Adya for two weeks. Following a series of tweets from a family friend after the patient passed away, Union Health Minister J P Nadda had sought details about the matter and said that the government would investigate and take necessary action.


    The regulatory body has asked Fortis' chief executive officer and managing director for copies of invoices, names of the medicines given to the patient, the quantity administered, and the price charged.


    The drug pricing organization had warned Fortis earlier that if it fails to respond, its team will inspect hospital records to collect information.


    "The reports suggest that apart from hospital charges, the billing includes the inflated cost of medicine, syringes, and injectables," it said in the letter. "The NPPA is mandated to enquire and take action in cases wherever there is a violation of Drug Price Control Order, 2013."

    chargedrugsEBITDAFortisFortis HealthcareFortis HospitalhospitalsJ P NaddaMRPNational Pharmaceutical Pricing AuthorityNPPAover pricingover pricing of drugsprofit after taxrejectsThe Drug Price Control Order
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok